Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide once-weekly versus sitagliptin once-daily as add-on to metformin and/or thiazolidinediones in adults with type 2 diabetes mellitus
2012-004827-19Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Aug 2013
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised trial of semaglutide in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Novo Nordisk. Primary endpoint: Change in HbA1c. Started Aug 2013; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2012-004827-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004827-19.